The pharmaceutical outsourcing giant Lonza has completed the expansion of its facilities in Visp, Valais. Thanks to this work, the company has new capacities for the production of antibody-drug conjugates (ADC).
This capacity increase underscores the strategic importance the company places on ADCs, Lonza wrote in a statement Wednesday.
The ADC market is set to experience solid growth, driven by growing demand for newer cancer therapies that are now better targeted. The company thus claims to be well positioned to take advantage of this trend.
/ATS
Related posts:
Man Sentenced for Blackmailing ex and Threatening to Kill Her in Canton of Lucerne
Rising Interest Impacts Younger Borrowers
The SEC issues regulations to regulate digital asset businesses insists that it does not support it...
Investors slashed 2.7 million Yulongshan three-bedroom agent: cost goes back 6 years | Second-hand p...
Ericsson fined over $200 million in US over corruption case in Iraq
The rise of the hydrogen era, the four major cities in Germany hit directly!Electric vehicles will a...
S&P 500 sectors at record highs: Tech shines, Utilities stumble
Management & Social Sciences - Issue 2014/2 - No. 17 - Performance and responsible business